UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from __________ to __________ Commission file number: 001-39102 TFF Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) (State or Other Jurisdiction of Incorpor ...

| --- | --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------|-------|-------|-------|-------|-------|-------|--------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Better Delivery, Better Therapy: Powerful Drug Delivery Solutions | | | | | | | | | | | | | | | | | | Corporate Investor Presentation March 2022 | | | | | | | Nasdaq: TFFP | 1 Safe Harbor Statement SPE ...

| --- | --- | --- | --- | --- | --- | --- | |-------------------------------------------------------------------|-------|-------|-------|-------|-------|--------------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Better Delivery, Better Therapy: Powerful Drug Delivery Solutions | | | | | | | | Corporate Investor Presentation March 2022 | | | | | | Nasdaq: TFFP | 1 Safe Harbor Statement SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This document conta ...

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q3 2021 Earnings Conference Call November 15, 2021 4:30 PM ET Company Participants Corey Davis - LifeSci Advisors Glenn Mattes - President & Chief Executive Officer Dr. Dale Christensen - Director of Clinical Development Dr. Bill Williams - University of Texas, Austin Kirk Coleman - Chief Financial Officer Chris Cano - Chief Operating Officer Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Sahil Kazmi - B. Riley Securities Michael Okunewitch - M ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-39102 TFF PHARMACEUTICALS, Inc. (Exact name of registrant as specified in its charter) Delaware 82-4344737 (State or other jurisdict ...

| --- | --- | --- | --- | --- | --- | --- | --- | |-------|--------------------------------------------------------|-------|-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Advanced Technology for Better Drug Delivery Options | | | | | | | | | Corporate Investor Presentation | | | | | | | SAFE HARBOR STATEMENT 2 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This document contains forward-looking state ...

TFF Pharmaceuticals, Inc. (NASDAQ:TFFP) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Corey Davis - LifeSci Advisors Glenn Mattes - President & Chief Executive Officer Dale Christensen - Director of Clinical Development Kirk Coleman - Chief Financial Officer Bill Williams - University of Texas, Austin Chris Cano - Chief Operating Officer & Head of Business Development Conference Call Participants Jonathan Aschoff - ROTH Capital Partners Michael Okunewitch - Maxim Group Sah ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 For the Quarterly Period Ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-39102 TFF PHARMACEUTICALS, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) 2600 Via Fortuna, Suite 360 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d ...

TFF Pharmaceuticals Inc. (NASDAQ:TFFP) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Paul Sagan – Investor Relations Glenn Mattes – President, Chief Executive Officer and Director Dale Christensen – Director-Clinical Development Kirk Coleman – Chief Financial Officer Bill Williams – Professor, University of Texas, Austin Chris Cano – Chief Operating Officer and Head-Business Development Conference Call Participants Jonathan Aschoff – ROTH Capital Partners Daniel Carlson – TW ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 001-39102 TFF PHARMACEUTICALS, Inc. (737) 802-1973 (Registrant's telephone number, including area code) Not Applicable (Former name, former ...